Imatinib is a BCR-ABL tyrosine kinase inhibitor used in treatment protocols for various leukaemias and solid tumours.
EML status history
First added in 2015 (TRS 994) for Chronic myeloid leukaemia, not elsewhere classified
Added in 2015 (TRS 994) for Gastrointestinal stromal tumour of unspecified gastrointestinal sites
Added in 2021 (TRS 1035) for B lymphoblastic leukaemia or lymphoma with t(9:22) (q34;q11.2); BCR-ABL1
- Oral > Solid: 100 mg; 400 mg